PRNewswire Bengaluru Karnataka [India] January 16 Bengaluru-based biotechnology startup CrisprBits Private Limited has ...

CRISPR-Cas9, often simply referred to as CRISPR, is a groundbreaking genetic editing technology that has revolutionized the ...

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an ...

Caribou has initiated the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial designed to evaluate a single infusion of CB-010 in adult patients with LN and ERL. CB-011, a ...

Recent advancements in genetic research are proving instrumental in the conservation of endangered species. Scientists are ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

What I've learned from my work in this field is that having a well-crafted commercial strategy is important for companies ...

BERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haurwitz, PhD, Caribou’s ...

Biochemist Jennifer Doudna, a faculty scientist at the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab), founder of the ...